Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
INVO FERTILITY INC (IVF)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$2.03-0.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IVF yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce operating losses to improve profitability | Operating losses improved from -$2.99M in 2025-Q2 to -$1.59M in 2026-Q1. | Intact | operating loss worsens beyond -$1.59M in next 4 quarters | Operating income: $-1.29M FY2026-Q2; GAAP. Published target: operating loss less negative than -$1.59M in next 4 quarters. Target period is not explicitly aligned with this observation. Aug 14, 2026-1,289,650 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 16, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk growth and platform-building story, not yet a proven profitable business. The multi-year view is on watch: management is advancing growth and clinic profitability priorities, while recent results remain below the industry cohort.
The valuation signal is mixed and low confidence: IVF screens cheap versus peers, while the expectations gap is negative, suggesting expectations may still be demanding relative to the model. The valuation measure fell sharply recently, but the evidence does not establish that the shares are inexpensive overall or that near-term risks are fully reflected.
Near term, revenue growth and higher clinic-level adjusted EBITDA show progress in expanding and scaling the clinic platform, and cash increased through 2026-Q2. However, IVF remains loss-making, earnings are erratic, and the estimated chance of a next-quarter miss is elevated; a guidance cut would be a meaningful setback.
Over the next few quarters, the key test is whether organic growth and acquisitions continue to lift clinic profitability while the company strengthens liquidity. A weakening jobs backdrop or lower guidance could weigh on the business, while continued strength from large Healthcare companies could support sector momentum. The evidence for the broader forward scenarios is limited.
For the 1-3 year view, IVF has early signs of platform progress but has not yet shown reliable company-wide profitability, and execution and economic risks remain high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Resolve Nasdaq listing and financial reporting issues |
| A primary condition in INVO FERTILITY INC's published investment case. The stated target is Nasdaq listing maintained and no further delisting notices in next 4 quarters. |
| Under Pressure |
| Nasdaq delisting occurs or new regulatory penalties arise |
Delisting notice received vs no notices target News confirms Nasdaq delisting notice for late filings in June 2026, despite Q2 earnings beat. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Sustain revenue growth through acquisitions and organic expansion | The company is expanding through acquisitions and forming partnerships. | Broken | revenue falls below $10.4M in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.00 → $-4.00 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-07-25 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-07-26 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-07-27 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-07-28 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-07-29 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-07-30 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-07-31 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-08-01 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-02 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-08-03 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-08-04 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-08-05 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-08-06 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-07 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-08 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-09 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-08-10 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-12 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-13 | $-8.00 | $16,461,000 | 1 / 1 |
| 2026-08-14 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-15 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-16 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-17 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-18 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-19 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-20 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-21 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-22 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-23 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-24 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-25 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-26 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-27 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-28 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-29 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-30 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-08-31 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-01 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-02 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-03 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-04 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-05 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-06 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-07 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-08 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-09 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-10 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-11 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-12 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-13 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-14 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-15 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-16 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-17 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-18 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-19 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-20 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-21 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-22 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-23 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-24 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-25 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-26 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-27 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-28 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-29 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-09-30 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-01 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-02 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-03 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-04 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-05 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-06 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-07 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-08 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-09 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-10 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-11 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-12 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-13 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-14 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-15 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-16 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-17 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-18 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-19 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-20 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-21 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-22 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-23 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-24 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-25 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-26 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-27 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-28 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-29 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-30 | $-1.00 | $16,460,999 | 1 / 1 |
| 2026-10-31 | $-4.00 | $16,460,999 | 1 / 1 |
| 2026-11-01 | $-4.00 | $16,460,999 | 1 / 1 |
| 2026-11-02 | $-4.00 | $16,460,999 | 1 / 1 |
| 2026-11-03 | $-4.00 | $16,460,999 | 1 / 1 |
| 2026-11-04 | $-4.00 | $16,460,999 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Monthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.